Found: 12
Select item for more details and to access through your institution.
Aggressive T‐cell lymphomas: 2024: Updates on diagnosis, risk stratification, and management.
- Published in:
- American Journal of Hematology, 2024, v. 99, n. 3, p. 439, doi. 10.1002/ajh.27165
- By:
- Publication type:
- Article
Bendamustine lymphodepletion is a well‐tolerated alternative to fludarabine and cyclophosphamide lymphodepletion for axicabtagene ciloleucel therapy for aggressive B‐cell lymphoma.
- Published in:
- American Journal of Hematology, 2023, v. 98, n. 11, p. 1751, doi. 10.1002/ajh.27069
- By:
- Publication type:
- Article
Current perspectives on resistance to chimeric antigen receptor T‐cell therapy and strategies to improve efficacy in B‐cell lymphoma.
- Published in:
- European Journal of Haematology, 2024, v. 112, n. 2, p. 144, doi. 10.1111/ejh.13964
- By:
- Publication type:
- Article
A phase 2 study of carfilzomib, cyclophosphamide and dexamethasone as frontline treatment for transplant-eligible MM with high-risk features (SGH-MM1).
- Published in:
- 2021
- By:
- Publication type:
- Letter
High-dose methotrexate is effective for prevention of isolated CNS relapse in diffuse large B cell lymphoma.
- Published in:
- Blood Cancer Journal, 2021, v. 11, n. 8, p. 1, doi. 10.1038/s41408-021-00535-y
- By:
- Publication type:
- Article
Microvascular network alterations in the retina of patients with Alzheimer's disease.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2014, v. 10, n. 2, p. 135, doi. 10.1016/j.jalz.2013.06.009
- By:
- Publication type:
- Article
Subcutaneous bortezomib combined with weekly cyclophosphamide and dexamethasone is an efficient and well tolerated regime in newly diagnosed multiple myeloma.
- Published in:
- British Journal of Haematology, 2015, v. 169, n. 5, p. 754, doi. 10.1111/bjh.13238
- By:
- Publication type:
- Article
Howell-Jolly bodies in systemic amyloidosis.
- Published in:
- 2018
- By:
- Publication type:
- letter
Marked hypereosinophilia and rash as initial presentation of acute myeloid leukemia with t(8;21).
- Published in:
- 2017
- By:
- Publication type:
- case study
Real-World Experience of Measurable Residual Disease Response and Prognosis in Acute Myeloid Leukemia Treated with Venetoclax and Azacitidine.
- Published in:
- Cancers, 2022, v. 14, n. 15, p. 3576, doi. 10.3390/cancers14153576
- By:
- Publication type:
- Article
Risk factors and predictors of treatment responses and complications in immune thrombocytopenia.
- Published in:
- Annals of Hematology, 2021, v. 100, n. 3, p. 645, doi. 10.1007/s00277-021-04424-z
- By:
- Publication type:
- Article
Rivaroxaban for heparin-induced thrombocytopenia: adding to the evidence.
- Published in:
- 2017
- By:
- Publication type:
- letter